

17 March 2022

April 2022 Pharmaceutical Schedule Dispatch

Kia ora

This is an early notification of the changes to be announced in the **April 2022** Update to the Pharmaceutical Schedule.

The full Update will be available as a [PDF on our website](#). The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

New listings

- Amino acid formula (Alfamino) powder, 400 g OP – Special Authority – Hospital Pharmacy [HP3] (p'code 2632187)
- Amino acid formula (Alfamino Junior) powder, 400 g OP – Special Authority – Hospital Pharmacy [HP3] (p'code 2634848)
- Oil in water emulsion (Fatty Cream AFT) crm, 500 g (p'code 2627426)
- Pharmacy services (BSF Cinacalcet Devatis) brand switch fee – may only be claimed once per patient (p'code 2634120)
- Pharmacy services (BSF Comtan) brand switch fee – may only be claimed once per patient (p'code 2634139)
- Pharmacy services (BSF Vigisom) brand switch fee – may only be claimed once per patient (p'code 2634112)

Changes to restrictions, chemical names and presentations

- Abiraterone acetate (Zytiga) tab 250 mg – amended Special Authority criteria
- Cinacalcet (Cinacalcet Devatis) tab 30 mg – addition of brand switch fee payable
- Entacapone (Comtan) tab 200 mg – addition of brand switch fee payable
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended Special Authority criteria
- Febuxostat (Febuxostat multichem) tab 80 mg and 120 mg – removal of brand switch fee payable
- Gefitinib (Iressa) tab 250 mg – amended Special Authority criteria
- Melatonin (Vigisom) tab modified-release 2 mg – addition of brand switch fee payable
- Nivolumab inj 10 mg per ml, 4 ml and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Octreotide long-acting (Octreotide Depot Teva) inj depot 10 mg, 20 mg and 30 mg prefilled syringe – amended Special Authority criteria

- Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Pregabalin cap 150 mg (Lyrica and Pregabalin Pfizer) and cap 300 mg (Pregabalin Pfizer) – removal of stat
- Rituximab (Riximyo) inj 100 mg per 10 ml vial, inj 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria
- Sunitinib (Sunitinib Pfizer and Sutent) cap 12.5 mg, 25 mg and 50 mg – amended Special Authority criteria
- Zoledronic acid (Aclasta) inj 0.05 mg per ml, 100 ml, vial, 100 ml OP – amended Special Authority criteria
- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml, vial – amended Special Authority criteria

Increased subsidy

| Chemical | Presentation | Fully subsidised brands |
|------------|--|-------------------------|
| Salmeterol | Aerosol inhaler CFC-free, 25 mcg per dose, 120 dose OP | Serevent |
| | Powder for inhalation, 50 mcg per dose, breath activated, 60 dose OP | Serevent Accuhaler |

Decreased subsidy

| Chemical | Presentation | Fully subsidised brands | Partially subsidised brands |
|----------------------------|----------------------|----------------------------------|-----------------------------|
| Aqueous cream | Crn, 500 g | Boucher GEM Aqueous Cream* | |
| Carbimazole | Tab 5 mg | Neo-Mercazole | |
| Carmustine | Inj 100 mg vial | BiCNU Bicnu Heritage* | |
| | Inj 1 mg for ECP | Baxter | |
| Colchicine | Tab 500 mcg | Colgout | |
| Promethazine hydrochloride | Tab 10 mg and 25 mg | Allersoothe | |
| Spirolactone | Tab 25 mg and 100 mg | Spiractin | |

* no subsidy change for these brands for 1 April 2022.